Evotec signs IPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
(RTTNews) – Evotec AG (EVTCY.PK), a German drug discovery and development company, announced on Tuesday that it has entered into a target and drug discovery partnership with Boehringer Ingelheim in ophthalmology.
The companies will focus on modeling diseases induced by pluripotent stem cells or iPSCs for ophthalmological disorders.
Evotec, through phenotypic screening of iPSC-derived human cells, supported by its PanOmics platform, will identify small molecules capable of modulating disease phenotypes. The company will then validate the underlying promising targets for potential therapeutic interventions.
Boehringer Ingelheim will then pursue the discovery and development of potential therapeutic candidates.
In addition to an undisclosed upfront payment and an FTE-based research payment, Evotec will continue to benefit from the successful further development of candidates in the form of tiered milestones and royalties.
Cord Dohrmann, Chief Scientific Officer of Evotec, said, “Phenotypic screening approaches have a long history of delivering highly effective drugs based on novel molecular mechanisms. deliver disease-relevant drugs than any other cell-based screening approach. »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.